文献速递肝病消化道肿瘤与早癌

儿童和年轻人丙型肝炎病毒感染的流行病学与自然史

Epidemiology and natural history of hepatitis C virus infection among children and young people.
PubMed 文献 · J Hepatol · 2018-11-27

该回顾性研究纳入英国HCV研究中的1049例儿童期HCV感染者,主要感染途径为静脉吸毒(53%)、血制品暴露(24%)和围产期感染(11%)。32%的患者在感染后中位33年发生肝病,围产期感染者肝硬化年龄更早;总体663例接受治疗,406例(75%)获得持续病毒学应答,未获得SVR者死亡率高于获得SVR者(5% vs 1%,p=0.003)。

要点

  • 儿童期HCV感染后32%在中位33年发生肝病,围产期感染者肝硬化年龄更早。
  • 663例接受治疗者中406例(75%)获得持续病毒学应答。
  • 未获得SVR者死亡率5% vs 获得SVR者1%(p=0.003)。

核心结论

  • 儿童期HCV感染可导致显著肝病,抗病毒治疗可预防;早期治疗、尤其在肝硬化发生前至关重要。
  • 应针对相关风险人群检测HCV,并在儿童期提供抗病毒治疗以预防长期肝病和HCV传播。

研究设计与样本

  • 本研究为回顾性综述,纳入英国HCV研究(HCV Research UK)中儿童期感染HCV的患者,共识别并纳入1049例。

主要发现

  • 主要感染途径为静脉吸毒(53%)、血制品暴露(24%)和围产期感染(11%)。
  • 32%的患者发生肝病,发生于感染后中位33年,与感染方式无关;围产期暴露者肝硬化年龄早于其他风险组。
  • 肝细胞癌发生率为5%,肝移植为4%,死亡发生于3%。
  • 共663例接受治疗(55%为干扰素/聚乙二醇干扰素,40%为直接抗病毒药物),406例(75%)获得持续病毒学应答。
  • 未获得SVR者死亡率高于获得SVR者(5% vs 1%,p=0.003);无肝硬化者治疗更有效,疾病进展频率(13%)低于治疗时已有肝硬化者(28%),p<0.001。

临床怎么用

  • 作者认为应针对相关风险人群检测HCV,并在儿童期提供抗病毒治疗以预防长期肝病和HCV传播。
  • 作者认为早期治疗、尤其在肝硬化发生前至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a global health burden. Although HCV infection rarely contributes to morbidity during childhood, most HCV-infected children develop chronic HCV with a lifetime risk of liver disease. Little is known about the development of long-term liver disease and the effect of treatment in patients infected with HCV in childhood. METHOD: This study was a retrospective review of patients infected with HCV in childhood enrolled in HCV Research UK. A total of 1,049 patients were identified and included. RESULTS: The main routes of infection were intravenous drug use (53%), blood product exposure (24%) and perinatal infection (11%). Liver disease developed in 32% of patients, a median of 33 years after infection, irrespective of the mode of infection. Therefore, patients with perinatal exposure developed cirrhosis at an earlier age than the rest of the risk groups. The incidence of hepatocellular carcinoma (HCC) was 5%, liver transplant 4% and death occurred in 3%. Overall, 663 patients were treated (55% with interferon/pegylated interferon and 40% with direct-acting antivirals). Sustained virological response (SVR) was achieved in 406 (75%). There was a higher mortality rate among patients without SVR vs. those with SVR (5% vs. 1%, p = 0.003). Treatment was more effective in patients without cirrhosis and disease progression was less frequent (13%) than in patients with cirrhosis at the time of therapy (28%) p < 0.001. Patients with cirrhosis were more likely to develop HCC, require liver transplantation, or die. CONCLUSION: HCV infection in young people causes significant liver disease, which can now be prevented with antiviral therapy. Early treatment, especially before development of cirrhosis is essential. Detection of HCV should be aimed at relevant risk groups and antiviral therapy should be made available in childhood to prevent long-term liver disease and spread of HCV. LAY SUMMARY: Chronic hepatitis C virus (HCV) infection is a global health problem, which can now be treated with potent direct-acting antiviral drugs. This study demonstrates that HCV infection in childhood causes serious liver disease in 32% of patients, a median of 33 years after infection, irrespective of age, mode and route of infection. Disease outcomes were better in patients treated before the development of advanced liver disease. Antiviral therapy should be made available in childhood to prevent long-term liver disease and the spread of HCV.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Modin L, Arshad A, Wilkes B, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2018. PMID: 30496763. doi:10.1016/j.jhep.2018.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。